JELMYTO® Shows Impressive 86% Recurrence-Free Survival (RFS) at 24 Months Across Varied Patient Profiles: Insights from AUA 2024 Retrospective Analysis
UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from a sub-analysis within the largest real-world patient cohort evaluation of JELMYTO (mitomycin) for pyelocalyceal solution, presented at the American Urological…
Exploring New Frontiers in Neuroscience with GE HealthCare’s SIGNA MAGNUS
GE HealthCare (Nasdaq: GEHC) has introduced SIGNA MAGNUS, a head-only magnetic resonance (MR) scanner awaiting FDA 510(k) approval. This cutting-edge technology aims to revolutionize neuroscience research, addressing the limitations of…
Genmab Announces Financial Results for the First Quarter of 2024
The U.S. Food and Drug Administration (U.S. FDA) has granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) aimed at treating adult patients with relapsed or…
Astellas and Poseida Therapeutics Collaborate to Advance Innovative Allogeneic Cell Therapies for Cancer Treatment
Astellas Pharma Inc. (TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have announced a strategic collaboration between Astellas’ subsidiary Xyphos Biosciences, Inc. and Poseida. The agreement aims to develop innovative…
4 Ideas for Honoring Teachers During Teacher Appreciation Week, May 6-10
Teacher Appreciation Week arrives annually during the first full week of May, serving as a dedicated time to recognize and celebrate the unwavering commitment of educators worldwide. It presents an…
Amgen Announces Financial Performance for Q1 2024
Summary of Financial Highlights: In the first quarter of 2024, the company experienced significant growth across various metrics: Overall, the company demonstrated robust growth in revenues and product sales, despite…
Alnylam Pharmaceuticals Releases Q1 2024 Financial Results and Highlights Recent Achievements
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced its financial results for the first quarter ending March 31, 2024, along with notable recent business achievements. Yvonne…
Moderna Unveils Financial Performance for Q1 2024 and Business Developments
Moderna, Inc. (NASDAQ: MRNA) has released its financial results for the first quarter of 2024, along with key updates on its business operations. Stéphane Bancel, the Chief Executive Officer of…
Biogen’s Advancements in Corporate Responsibility Initiatives
Biogen Inc. (Nasdaq: BIIB) has released its 2023 Corporate Responsibility Report, illustrating the company’s strides in adhering to ethical business practices for the betterment of all stakeholders. Christopher A. Viehbacher,…
Novartis Strikes Deal to Purchase Mariana Oncology, Bolstering Radioligand Therapy Portfolio
Novartis to Acquire Mariana Oncology, Enhancing Radioligand Therapy Portfolio Novartis has announced its agreement to acquire Mariana Oncology, a biotechnology company headquartered in Watertown, Massachusetts, specializing in the development of…
Calquence Combo Shows Significant Progression-Free Survival Boost in 1st-Line Mantle Cell Lymphoma: ECHO Phase III Study
Encouraging findings emerge from an interim analysis of the ECHO Phase III trial, indicating that AstraZeneca’s Calquence (acalabrutinib), when paired with standard-of-care chemoimmunotherapy—bendamustine and rituximab—achieved a significant improvement in progression-free…
Novo Nordisk’s Q1 2024 Revenue Surges: Up by 22% in Danish Kroner, 24% at Constant Exchange Rates, Reaching DKK 65.3 Billion
Novo Nordisk’s Q1 2024 Performance Highlights Growth and Expansion Novo Nordisk, a global healthcare company focusing on diabetes and other serious chronic diseases, has reported robust financial results for the…